Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases

Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies. The post Novo Nordisk Bets $200M on Triple-Targeting Drug for…

Read More

An Arm and a Leg: New Lessons in the Fight for Charity Care

Federal law requires that all nonprofit hospitals have financial assistance policies — also known as “charity care” — to reduce or expunge people’s medical bills. New research from Dollar For, an organization dedicated to helping people get access to charity care, suggests that fewer than one-third of people who qualify for charity care actually receive…

Read More

What the Health? From KFF Health News: 40 Years of Health Policy

The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…

Read More

Musk Moves US to Socialized Medicine

By THCB STAFF After a few weeks analyzing government spending and putting all of his calculations into Grok, the head of DOGE, Elon Musk, has made another decisive move in the attempt to save the government money. Speaking on the Joe Rogan show, Musk declared that his team had given Big Balls and Little Balls…

Read More